ID
11638
Beschrijving
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis ODM derived from http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Link
http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Trefwoorden
Versies (2)
- 24-11-11 24-11-11 -
- 09-07-15 09-07-15 - Martin Dugas
Geüploaded op
9 juli 2015
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Psoriasis NCT00216879
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI-1
- C0680251
Beschrijving
PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation
Datatype
boolean
Alias
- UMLS CUI-1
- C0853073
- UMLS CUI-2
- C0018233
Beschrijving
UVB therapy anywhere on the patient within 14 days prior to randomisation
Datatype
boolean
Alias
- UMLS CUI-1
- C0564461
Beschrijving
Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton
Datatype
boolean
Alias
- UMLS CUI-1
- C0005522
Beschrijving
Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation
Datatype
boolean
Alias
- UMLS CUI-1
- C1515119
Beschrijving
Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton
Datatype
boolean
Alias
- UMLS CUI-1
- C0150349
Beschrijving
Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation
Datatype
boolean
Alias
- UMLS CUI-1
- C0150349
- UMLS CUI-2
- C0001617
Beschrijving
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
Datatype
boolean
Alias
- UMLS CUI-1
- C2347852
Beschrijving
Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis
Datatype
boolean
Alias
- UMLS CUI-1
- C0343052
- UMLS CUI-2
- C0152081
- UMLS CUI-3
- C0748052
Beschrijving
Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
Datatype
boolean
Alias
- UMLS CUI-1
- C0037278
Beschrijving
Known or suspected severe renal insufficiency or severe hepatic disorders
Datatype
boolean
Alias
- UMLS CUI-1
- C1565489
- UMLS CUI-2
- C1869009
Beschrijving
Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia
Datatype
boolean
Alias
- UMLS CUI-1
- C0020437
Beschrijving
Trial subjects should be using an adequate method of contraception
Datatype
boolean
Alias
- UMLS CUI-1
- C0700589
Similar models
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
C0018233 (UMLS CUI-2)
C0001617 (UMLS CUI-2)
C0152081 (UMLS CUI-2)
C0748052 (UMLS CUI-3)
C1869009 (UMLS CUI-2)